Market Overview

Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184

Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.

Posted-In: News FDA Movers


Related Articles (IDIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters